US20230082575A1 - Slow release pharmaceutical composition made of microparticles - Google Patents

Slow release pharmaceutical composition made of microparticles Download PDF

Info

Publication number
US20230082575A1
US20230082575A1 US17/932,621 US202217932621A US2023082575A1 US 20230082575 A1 US20230082575 A1 US 20230082575A1 US 202217932621 A US202217932621 A US 202217932621A US 2023082575 A1 US2023082575 A1 US 2023082575A1
Authority
US
United States
Prior art keywords
microparticles
micrometers
pharmaceutical composition
microgranules
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/932,621
Inventor
Bertrand Ducrey
Patrick Garrouste
Catherine Curdy
Marie-Anne Bardet
Herve Porchet
Eija Lundstrom
Frederic Heimgartner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Debiopharm International SA
Original Assignee
Debiopharm International SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40032512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20230082575(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Debiopharm International SA filed Critical Debiopharm International SA
Priority to US17/932,621 priority Critical patent/US20230082575A1/en
Publication of US20230082575A1 publication Critical patent/US20230082575A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Definitions

  • the invention relates to pharmaceutical compositions made of microparticles which are used for the slow release of an active substance.
  • compositions which comprise a copolymer of lactic and glycolic acid (PLGA) incorporating, as active substance, a water insoluble peptide salt.
  • PLGA lactic and glycolic acid
  • compositions as defined above are disclosed in Swiss patent CH 679 207 A5.
  • microparticle has to be understood as a solid object of any shape, e.g. microsphere or microgranule, having a median diameter of less than 250 micrometers.
  • D (v,0.5), also mentioned as “median diameter”, means that 50 of the microparticles have a diameter which is less than the indicated value.
  • D (v,0.1) means that 10% of the microparticles have a diameter which is less than the indicated value and D (v,0.9) means that 90% of the microparticles have a diameter which is less than the indicated value.
  • microgranule refers to an object which is the result of a milling operation on an elongated product such as an extrudate.
  • PLGA XX/YY refers to a poly(D,L lactide-co-glycolide), where XX represents the lactide content, and YY represents the glycolide content. The ratio lactide/glycolide being expressed in mol percent.
  • month refers to 28 days.
  • the objective of the invention is to offer several improvements with respect to the state of the art.
  • One of those improvements is to provide a continuous and efficient slow release of the active substance during at least a period covering the 6 th month after injection of the composition.
  • the invention concerns a pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the 6 th month after injection of said composition, said composition comprising a group of microparticles made of a copolymer of the PLGA type which incorporate an active substance in the form of a water insoluble peptide salt; said copolymer furthermore comprising at least 75% of lactic acid and an inherent viscosity between 0.1 and 0.9 dl/g, as measured in chloroform at 25° C. and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows:
  • the composition consists of one single group of microparticles.
  • the lactide content of the PLGA is of at least 85% and the inherent viscosity is between 0.1 and 0.4 dl/g.
  • a release during at least 6 months can be obtained with the composition of this first embodiment.
  • the microparticles may be microspheres or microgranules.
  • the composition comprises a group of microparticles wherein the lactide content of the PLGA is of at least 85% and the inherent viscosity is preferably between 0.5 and 0.9 dl/g and more preferably between 0.63 and 0.67 dl/g.
  • microparticles may be microspheres or microgranules
  • the group of microparticles defined in the second embodiment may advantageously be used for providing a slow and significant release during at least a period starting from the 4 th month after injection of the composition until and including the 6 th month.
  • the pharmaceutical composition furthermore comprises another group of microparticles made of a copolymer of the PLGA type having a lactide content between 70% and 80% which incorporates said active substance.
  • Both groups of microparticles may be present in a dose ratio (expressed in peptide content) close to 50:50.
  • the inherent viscosity of each group is between 0.5 and 0.9 dl/g.
  • the inherent viscosity of the other group is between 0.60 and 0.70 dl/g and in particular 0.65 dl/g and the inherent viscosity of the first group is the same as the one defined in the second embodiment.
  • microparticles of the other group may be microgranules or microspheres.
  • both groups of microparticles are microgranules.
  • One group of microparticules is advantageously obtained by mixing, in a solvent-free process, said PLGA with said water insoluble peptide salt.
  • one group may be used to provide a slow and significant release of the water insoluble peptide salt during at least the first three months after injection of the composition while the other group is used for a release starting from the 4 th month.
  • the active substance is a LHRH agonist triptorelin (used as water insoluble salt such as the pamoate salt thereof) which may be efficiently used in the treatment of prostate cancer.
  • the LHRH agonist triptorelin is released in an important immediate amount within hours following injection and then shows a constant and significant release over a long period of at least 168 days, i.e. 6 months
  • FIG. 1 shows triptorelin, LHRH agonist, serum levels obtained with the pharmaceutical biodegradable composition of example 1,
  • FIG. 2 shows triptorelin, LHRH agonist, serum levels obtained with the pharmaceutical biodegradable composition of example 3,
  • FIG. 3 shows triptorelin, LHRH agonist, serum levels obtained with the pharmaceutical biodegradable composition of example 4,
  • the viscosity is expressed in dl/g and is measured at a polymer concentration of 0.5 g/dl.
  • triptorelin pamoate 3000 mg are suspended in 30 g of ethyl acetate and placed under magnetic stirring. This solution is incorporated to the organic phase previously prepared. The organic phase is then introduced in a homogenisation chamber simultaneously with the said aqueous phase. Both phases are mixed in order to obtain an emulsion and the extraction of the solvent from the organic phase and to isolate a suspension of microspheres.
  • microspheres is recovered by filtration and dried by lyophilization.
  • microspheres have a size distribution defined as follows:
  • a formulation of microgranules of triptorelin pamoate is prepared as described in example 1.
  • microgranules is prepared as described in example 1 with PLGA 85/15 having an inherent viscosity of 0.66 dl/g.
  • the 2 formulations of microgranules are mixed in a vial in order to have a 50:50 dose ratio of each formulation.
  • the mixture is suspended in an appropriate aqueous medium, lyophilised and sterilized by gamma irradiation.
  • the purity measured on the obtained pharmaceutical biodegradable composition is 98.8% and the burst evaluated in vitro (in a phosphate buffer pH 7.4) over a 6 hours period is 45.0%.
  • a formulation of microspheres of triptorelin pamoate and PLGA 95/5 having an inherent viscosity of 0.18 dl/g is prepared as follows:
  • Aqueous phase is prepared by mixing, under magnetic stirring, at a temperature of 40° C., 800 g of polyvinyl alcohol and 40 L of purified water.
  • the organic phase is prepared by total dissolution of 80 g of PLGA 95/5 in 334 g of isopropyl acetate under magnetic stirring.
  • microspheres is recovered by filtration and dried by lyophilization.
  • microspheres have a size distribution defined as follows:
  • This formulation of microspheres is suspended in an appropriate aqueous medium, lyophilised and sterilized by gamma irradiation.
  • the purity measured on the obtained pharmaceutical biodegradable composition is 99.2% and the burst evaluated in vitro (in a phosphate buffer pH 7.4) over a 6 hours period is 10.9%.
  • the median relative decreases in PSA from baseline were 96.9% at Week 24, and 96.4% at Week 48, when 80.9% of patients had a normal PSA.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the 6th month after injection of said composition, said composition comprising a group of microparticles made of a copolymer of the PLGA type which incorporate an active substance in the form of a water insoluble peptide salt; said copolymer furthermore comprising at least 75% of lactic acid and an inherent viscosity between 0.1 and 0.9 dl/g, as measured in chloroform at 25° C. and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows:—D (v,0.1) is between 10 and 30 micrometers,—D (v,0.5) is between 30 and 70 micrometers,—D(v,0.9) is between 50 and 110 micrometers.

Description

    FIELD OF INVENTION
  • The invention relates to pharmaceutical compositions made of microparticles which are used for the slow release of an active substance.
  • It more precisely relates to such compositions which comprise a copolymer of lactic and glycolic acid (PLGA) incorporating, as active substance, a water insoluble peptide salt.
  • STATE OF THE ART
  • Compositions as defined above are disclosed in Swiss patent CH 679 207 A5.
  • DEFINITIONS
  • In the present text, the term “microparticle” has to be understood as a solid object of any shape, e.g. microsphere or microgranule, having a median diameter of less than 250 micrometers.
  • The expression D (v,0.5), also mentioned as “median diameter”, means that 50 of the microparticles have a diameter which is less than the indicated value.
  • Hence, if D (v,0.5)=55 micrometers, 50% of the microparticles have a diameter which is less than 55 micrometers.
  • In the same way, D (v,0.1) means that 10% of the microparticles have a diameter which is less than the indicated value and D (v,0.9) means that 90% of the microparticles have a diameter which is less than the indicated value.
  • All above values are measured by laser diffraction.
  • The term “microgranule” refers to an object which is the result of a milling operation on an elongated product such as an extrudate.
  • The term PLGA XX/YY refers to a poly(D,L lactide-co-glycolide), where XX represents the lactide content, and YY represents the glycolide content. The ratio lactide/glycolide being expressed in mol percent.
  • The term “month” refers to 28 days.
  • GENERAL DESCRIPTION OF THE INVENTION
  • The objective of the invention is to offer several improvements with respect to the state of the art.
  • One of those improvements is to provide a continuous and efficient slow release of the active substance during at least a period covering the 6th month after injection of the composition.
  • To this effect the invention concerns a pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the 6th month after injection of said composition, said composition comprising a group of microparticles made of a copolymer of the PLGA type which incorporate an active substance in the form of a water insoluble peptide salt; said copolymer furthermore comprising at least 75% of lactic acid and an inherent viscosity between 0.1 and 0.9 dl/g, as measured in chloroform at 25° C. and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows:
      • D (v,0.1) is between 10 and 30 micrometers,
      • D (v,0.5) is between 30 and 70 micrometers,
      • D(v,0.9) is between 50 and 110 micrometers.
  • In a first embodiment, the composition consists of one single group of microparticles. In that case the lactide content of the PLGA is of at least 85% and the inherent viscosity is between 0.1 and 0.4 dl/g.
  • A release during at least 6 months can be obtained with the composition of this first embodiment.
  • The microparticles may be microspheres or microgranules.
  • In a second embodiment, the composition comprises a group of microparticles wherein the lactide content of the PLGA is of at least 85% and the inherent viscosity is preferably between 0.5 and 0.9 dl/g and more preferably between 0.63 and 0.67 dl/g.
  • The microparticles may be microspheres or microgranules
  • The group of microparticles defined in the second embodiment may advantageously be used for providing a slow and significant release during at least a period starting from the 4th month after injection of the composition until and including the 6th month.
  • In a third embodiment, the pharmaceutical composition furthermore comprises another group of microparticles made of a copolymer of the PLGA type having a lactide content between 70% and 80% which incorporates said active substance.
  • Both groups of microparticles may be present in a dose ratio (expressed in peptide content) close to 50:50.
  • The inherent viscosity of each group is between 0.5 and 0.9 dl/g.
  • Preferably the inherent viscosity of the other group is between 0.60 and 0.70 dl/g and in particular 0.65 dl/g and the inherent viscosity of the first group is the same as the one defined in the second embodiment.
  • The microparticles of the other group may be microgranules or microspheres.
  • Advantageously both groups of microparticles are microgranules.
  • One group of microparticules is advantageously obtained by mixing, in a solvent-free process, said PLGA with said water insoluble peptide salt.
  • When two groups of microparticles are present, one group may be used to provide a slow and significant release of the water insoluble peptide salt during at least the first three months after injection of the composition while the other group is used for a release starting from the 4th month.
  • In a preferred embodiment the active substance is a LHRH agonist triptorelin (used as water insoluble salt such as the pamoate salt thereof) which may be efficiently used in the treatment of prostate cancer.
  • The LHRH agonist triptorelin is released in an important immediate amount within hours following injection and then shows a constant and significant release over a long period of at least 168 days, i.e. 6 months
  • DETAILED DESCRIPTION OF THE INVENTION
  • The invention is discussed below in a more detailed way with examples, the first being illustrated by the following figure:
  • FIG. 1 shows triptorelin, LHRH agonist, serum levels obtained with the pharmaceutical biodegradable composition of example 1,
  • FIG. 2 shows triptorelin, LHRH agonist, serum levels obtained with the pharmaceutical biodegradable composition of example 3,
  • FIG. 3 shows triptorelin, LHRH agonist, serum levels obtained with the pharmaceutical biodegradable composition of example 4,
  • In the following examples the viscosity is expressed in dl/g and is measured at a polymer concentration of 0.5 g/dl.
  • EXAMPLE 1
      • A formulation of microgranules of triptorelin pamoate is prepared with the following process.
      • Approximately 12% (w/w) of triptorelin pamoate is mixed with approximately 88% (w/w) PLGA 75/25 having a viscosity of 0,65 dl/g, at room temperature. The given mixture is duly homogenized, subjected to progressive compression and simultaneously to a progressive heating, before extrusion. The extrudate is cut into pellets and ground at a temperature of about −100° C. The microgranules obtained after grinding are sieved below 180 micrometers. Their size distribution is defined as follows:
      • D (v,0.1)=23 micrometers
      • D (v,0.5)=55 micrometers
      • D (v,0.9)=99 micrometers
      • A formulation of microspheres of triptorelin pamoate and PLGA 85/15 having an inherent viscosity of 0.68 dl/g is prepared as follows:
      • Aqueous phase is prepared by mixing, under magnetic stirring, at a temperature of 40° C., 240 g of polyvinyl alcohol and 11760 g of purified water. In parallel, the organic phase is prepared by total dissolution of 12 g of polymer 85/15 poly(D,L lactide-co-glycolide) (PLGA) in 45 g of ethyl acetate under magnetic stirring.
  • 3000 mg of triptorelin pamoate are suspended in 30 g of ethyl acetate and placed under magnetic stirring. This solution is incorporated to the organic phase previously prepared. The organic phase is then introduced in a homogenisation chamber simultaneously with the said aqueous phase. Both phases are mixed in order to obtain an emulsion and the extraction of the solvent from the organic phase and to isolate a suspension of microspheres.
  • Finally the formulation of microspheres is recovered by filtration and dried by lyophilization.
  • The microspheres have a size distribution defined as follows:
      • D (v,0.1)=15.6 micrometers
      • D (v,0.5)=33.4 micrometers
      • D (v,0.9)=60.8 micrometers
      • The formulation of microspheres and the formulation of microgranules are mixed in a vial in order to have a 50:50 dose ratio of each formulation. The mixture is suspended in an appropriate aqueous medium, lyophilised and sterilized by gamma irradiation.
      • The purity measured on the obtained pharmaceutical biodegradable composition is 98.3% and the burst evaluated in vitro (in a phosphate buffer pH 7.4) over a 6 hours period is 22.1%.
      • In this example, the obtained pharmaceutical formulation is tested in vivo and the animal model is the rat. The formulation as described above is suspended in water for injection and is administered at a concentration dose of 18 mg/kg to 6 rats.
      • The LHRH agonist triptorelin of said pharmaceutical biodegradable composition is released in an important immediate amount within hours following injection and then shows a constant and significant release over a long period of at least 168 days, i.e. 6 months.
    EXAMPLE 2
      • A formulation of microgranules of triptorelin pamoate is prepared as described in example 1.
      • A formulation of microspheres of triptorelin pamoate is prepared as described in example 1 with PLGA 90/10 having an inherent viscosity of 0.7 dl/g. The microspheres have a size distribution defined as follows:
      • D (v,0.1)=17.6 micrometers
      • D (v,0.5)=39.9 micrometers
      • D (v,0.9)=84.2 micrometers
      • The formulation of microspheres and the formulation of microgranules are mixed in a vial in order to have a 50:50 dose ratio of each formulation. The mixture is suspended in an appropriate aqueous medium, lyophilised and sterilized by gamma irradiation.
      • The purity measured on the obtained pharmaceutical biodegradable composition is 98.3% and the burst evaluated in vitro (in a phosphate buffer pH 7.4) over a 6 hours period is 19.4%.
      • The LHRH agonist triptorelin of said pharmaceutical biodegradable composition is released in an important immediate amount within hours following injection and then shows a constant and significant release over a long period of at least 168 days, i.e. 6 months.
    EXAMPLE 3
  • A formulation of microgranules of triptorelin pamoate is prepared as described in example 1.
  • Another formulation of microgranules is prepared as described in example 1 with PLGA 85/15 having an inherent viscosity of 0.66 dl/g.
  • Approximately 20% (w/w) of triptorelin pamoate is mixed with approximately 80% (w/w) PLGA 85/15 at room temperature. The given mixture is duly homogenized, subjected to progressive compression and simultaneously to a progressive heating, before extrusion. The extrudate is cut into pellets and ground at a temperature of about −100° C. The microgranules obtained after grinding are sieved below 180 micrometers. Their size distribution is defined as follows
      • D (v,0.1)=20.5 micrometers
      • D (v,0.5)=51.7 micrometers
      • D (v,0.9)=96.9 micrometers
  • The 2 formulations of microgranules are mixed in a vial in order to have a 50:50 dose ratio of each formulation. The mixture is suspended in an appropriate aqueous medium, lyophilised and sterilized by gamma irradiation.
  • The purity measured on the obtained pharmaceutical biodegradable composition is 98.8% and the burst evaluated in vitro (in a phosphate buffer pH 7.4) over a 6 hours period is 45.0%.
      • In this example, the obtained pharmaceutical formulation is tested in vivo and the animal model is the rat. The formulation as described above is suspended in water for injection and is administered at a concentration dose of 18 mg/kg to 6 rats.
      • The LHRH agonist triptorelin of said pharmaceutical biodegradable composition is released in an important immediate amount within hours following injection and then shows a constant and significant release over a long period of at least 168 days, i.e. 6 months (see FIG. 2 ).
    EXAMPLE 4
  • A formulation of microspheres of triptorelin pamoate and PLGA 95/5 having an inherent viscosity of 0.18 dl/g is prepared as follows:
  • Aqueous phase is prepared by mixing, under magnetic stirring, at a temperature of 40° C., 800 g of polyvinyl alcohol and 40 L of purified water. In parallel, the organic phase is prepared by total dissolution of 80 g of PLGA 95/5 in 334 g of isopropyl acetate under magnetic stirring.
  • 20 g of triptorelin pamoate are suspended in 100 g of isopropyl acetate and placed under magnetic stirring. This solution is incorporated to the organic phase previously prepared. The organic phase is then introduced in a homogenisation chamber simultaneously with the said aqueous phase. Both phases are mixed in order to obtain an emulsion and the extraction of the solvent from the organic phase and to isolate a suspension of microspheres.
  • Finally the formulation of microspheres is recovered by filtration and dried by lyophilization.
  • The microspheres have a size distribution defined as follows:
      • D (v,0.1)=17.8 micrometers
      • D (v,0.5)=37.1 micrometers
      • D (v,0.9)=74.8 micrometers
  • This formulation of microspheres is suspended in an appropriate aqueous medium, lyophilised and sterilized by gamma irradiation.
  • The purity measured on the obtained pharmaceutical biodegradable composition is 99.2% and the burst evaluated in vitro (in a phosphate buffer pH 7.4) over a 6 hours period is 10.9%.
      • In this example, the obtained pharmaceutical formulation is tested in vivo and the animal model is the rat. The formulation as described above is suspended in water for injection and is administered at a concentration dose of 18 mg/kg to 6 rats.
      • The LHRH agonist triptorelin of said pharmaceutical biodegradable composition is released in an important immediate amount within hours following injection and then shows a constant and significant release over a long period of at least 168 days, i.e. 6 months (see FIG. 3 ).
    EXAMPLE 5
  • In order to increase patients' compliance and convenience the inventors also developed a formulation as defined in previous example 3 which allows one injection every 6 Months (24 Weeks). The study discussed in this example investigated the efficacy and safety of this formulation after 2 consecutive intramuscular injections of triptorelin pamoate 22.5 mg in 120 patients with advanced prostate cancer. Four-weekly testosterone assessments were performed over 48 weeks.
  • Serum testosterone concentrations fell to castrate levels (1.735 nmol/L) in 97.5% of the patients on D29, and 93% of the patients maintained castration from Week 8 to 48. Five out of 8 patients who escaped castration had only an isolated testosterone breakthrough without rising PSA (Prostate Specific Antigen), indicating maintained efficacy. Only one of these isolated breakthroughs was a true “acute-on-chronic” phenomenon after the second injection.
  • The median relative decreases in PSA from baseline were 96.9% at Week 24, and 96.4% at Week 48, when 80.9% of patients had a normal PSA.
  • The type and incidence of AEs (Adverse Events) were comparable with those observed with the registered triptorelin formulations. As with other GnRH agonists, the most frequent drug related AEs were hot flushes (71.7% of patients). The study drug was very well tolerated locally.
  • The study discussed above shows that Triptorelin 6-Month formulation is efficacious and safe in inducing chemical castration in patients with advanced prostate cancer. This new convenient formulation requires only 1 injection every 24 weeks, and shows comparable efficacy and safety with the marketed 1- and 3-Month formulations.

Claims (5)

1-15. (canceled)
16. A pharmaceutical composition comprising microparticles comprising 22.5 mg triptorelin in the form of triptorelin pamoate, wherein the microparticles are made of poly(D,L lactide-co-glycolide) (PLGA), wherein the PLGA comprises at least 75% lactide, and wherein the triptorelin pamoate is released from the pharmaceutical composition in an immediate amount within hours following injection into a patient and then constantly released over a period of at least 168 days, wherein the composition comprises two groups of microparticles, wherein the two groups of microparticles are a first group of microgranules and a second group of microgranules.
17. The pharmaceutical composition of claim 16, wherein the first group of microgranules and the second group of microgranules are mixed to have a 50:50 dose ratio of triptorelin.
18. The pharmaceutical composition of claim 16, wherein the pharmaceutical composition is administered to the patient once about every six months.
19. The pharmaceutical composition of claim 16, wherein the PLGA in the first group of microgranules comprises at least 85% lactide.
US17/932,621 2007-06-06 2022-09-15 Slow release pharmaceutical composition made of microparticles Pending US20230082575A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/932,621 US20230082575A1 (en) 2007-06-06 2022-09-15 Slow release pharmaceutical composition made of microparticles

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP07109767 2007-06-06
EP07109767.9 2007-06-06
IB2007054372 2007-10-27
IBPCT/IB2007/054372 2007-10-27
PCT/IB2008/052241 WO2008149320A2 (en) 2007-06-06 2008-06-06 Slow release pharmaceutical composition made of microparticles
US60164910A 2010-04-20 2010-04-20
US16/192,674 US20190192423A1 (en) 2007-06-06 2018-11-15 Slow Release Pharmaceutical Composition Made of Microparticles
US17/932,621 US20230082575A1 (en) 2007-06-06 2022-09-15 Slow release pharmaceutical composition made of microparticles

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US16/192,674 Continuation US20190192423A1 (en) 2007-06-06 2018-11-15 Slow Release Pharmaceutical Composition Made of Microparticles

Publications (1)

Publication Number Publication Date
US20230082575A1 true US20230082575A1 (en) 2023-03-16

Family

ID=40032512

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/601,649 Active 2029-02-10 US10166181B2 (en) 2007-06-06 2008-06-06 Slow release pharmaceutical composition made of microgranules
US16/192,674 Abandoned US20190192423A1 (en) 2007-06-06 2018-11-15 Slow Release Pharmaceutical Composition Made of Microparticles
US17/932,621 Pending US20230082575A1 (en) 2007-06-06 2022-09-15 Slow release pharmaceutical composition made of microparticles

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US12/601,649 Active 2029-02-10 US10166181B2 (en) 2007-06-06 2008-06-06 Slow release pharmaceutical composition made of microgranules
US16/192,674 Abandoned US20190192423A1 (en) 2007-06-06 2018-11-15 Slow Release Pharmaceutical Composition Made of Microparticles

Country Status (32)

Country Link
US (3) US10166181B2 (en)
EP (3) EP2500014B1 (en)
JP (1) JP5419169B2 (en)
KR (1) KR101631475B1 (en)
CN (1) CN101677959B (en)
AP (1) AP3000A (en)
AU (1) AU2008259411B2 (en)
BR (1) BRPI0812250B8 (en)
CA (1) CA2688478C (en)
CO (1) CO6251234A2 (en)
CY (2) CY1118434T1 (en)
DK (2) DK2164467T3 (en)
EA (1) EA019284B1 (en)
ES (2) ES2694401T3 (en)
HK (1) HK1141737A1 (en)
HR (2) HRP20161785T1 (en)
HU (2) HUE040391T2 (en)
IL (1) IL202501A (en)
LT (2) LT2164467T (en)
MA (1) MA31422B1 (en)
ME (1) ME00959B (en)
MX (1) MX2009012856A (en)
MY (1) MY150450A (en)
NZ (1) NZ582423A (en)
PL (2) PL2164467T3 (en)
PT (2) PT2500014T (en)
RS (2) RS55591B1 (en)
SI (2) SI2164467T1 (en)
TN (1) TN2009000476A1 (en)
UA (1) UA99830C2 (en)
WO (1) WO2008149320A2 (en)
ZA (1) ZA200907940B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99830C2 (en) 2007-06-06 2012-10-10 Дебио Ресшерчи Фармасютикю С.А. Slow release pharmaceutical composition made of microparticles
PT105270B (en) 2010-08-26 2012-05-31 Domino Ind Ceramicas S A LAYER OF SILICA WITH SLOW RELEASE OF FRAGRANCE, CERAMIC TILE AND RESPECTIVE PRODUCTION PROCESS
CN105267153B (en) * 2015-11-27 2018-05-11 上海苏豪逸明制药有限公司 A kind of Triptorelin sustained-release microparticle and preparation method thereof
CN105797134B (en) * 2016-03-29 2019-06-14 浙江圣兆药物科技股份有限公司 A kind of indissoluble Leuprorelin sustained release preparation
EP3535297B1 (en) 2016-11-02 2022-08-10 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
KR102402639B1 (en) 2017-11-24 2022-05-26 삼성전자주식회사 Electronic device and method for communicating thereof
CN111000798B (en) * 2019-12-26 2021-11-23 四川恒博生物科技有限公司 Non-operative castration injection for dogs by adopting in-situ gel technology
IT202000017191A1 (en) 2020-07-15 2022-01-15 Xbrane Biopharma Ab WATERLESS PROCESS FOR PREPARING A PHARMACEUTICAL COMPOSITION FOR A LONGER AND CONTROLLED RELEASE OF TRIPTORELIN OR A SALT ITS

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3678308D1 (en) 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd METHOD FOR PRODUCING MICROCAPSULES.
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH679207A5 (en) * 1989-07-28 1992-01-15 Debiopharm Sa
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
CH683149A5 (en) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Process for the preparation of microspheres of a biodegradable polymeric material.
FR2693905B1 (en) * 1992-07-27 1994-09-02 Rhone Merieux Process for the preparation of microspheres for the sustained release of the hormone LHRH and its analogs, microspheres and formulations obtained.
JP3277342B2 (en) 1992-09-02 2002-04-22 武田薬品工業株式会社 Manufacturing method of sustained release microcapsules
EP0724431B1 (en) * 1993-10-22 2002-09-11 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US5945128A (en) * 1996-09-04 1999-08-31 Romano Deghenghi Process to manufacture implants containing bioactive peptides
AR012448A1 (en) * 1997-04-18 2000-10-18 Ipsen Pharma Biotech COMPOSITION IN THE FORM OF MICROCAPSULES OR IMPLANTS COMPRISING A BIODEGRADABLE CONTAINER, POLYMER OR CO-POLYMER, OR A MIXTURE OF SUCH EXCIPIENTS, AND AN ACTIVE SUBSTANCE OR MIXTURE OF ACTIVE SUBSTANCES, PROCEDURE FOR THE PREPARATION OF A SUBSTANCE IN A SUBSTANCE
WO1999024061A1 (en) * 1997-11-07 1999-05-20 Chiron Corporation Method for producing igf-1 sustained-release formulations
TWI284048B (en) * 2000-01-27 2007-07-21 Zentaris Ag Compressed microparticles for dry injection
US20040170665A1 (en) 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
MXPA04003433A (en) * 2001-10-10 2004-08-11 Pf Medicament Prolonged release biodegradable microspheres and method for preparing same.
EP1617859A1 (en) * 2003-04-30 2006-01-25 Debiopharm S.A. Methods and compositions using gonadotropin hormone releasing hormone
KR100466637B1 (en) * 2003-06-26 2005-01-13 주식회사 펩트론 Method for preparing a mixed formulation of sustained release microspheres by continuous one-step process
FR2865938B1 (en) * 2004-02-05 2006-06-02 Sod Conseils Rech Applic SOLID DELAY FORMULATION COMPRISING TRIPTORELINE ACETATE
PT1968549E (en) 2005-12-22 2014-08-29 Novartis Ag Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers
UA99830C2 (en) 2007-06-06 2012-10-10 Дебио Ресшерчи Фармасютикю С.А. Slow release pharmaceutical composition made of microparticles

Also Published As

Publication number Publication date
UA99830C2 (en) 2012-10-10
EP2500014A2 (en) 2012-09-19
AP3000A (en) 2014-10-31
EP2500014A3 (en) 2012-11-07
HRP20161785T1 (en) 2017-03-10
PL2500014T3 (en) 2019-04-30
HUE031550T2 (en) 2017-07-28
AU2008259411A1 (en) 2008-12-11
AU2008259411B2 (en) 2013-10-17
RS55591B1 (en) 2017-06-30
HUE040391T2 (en) 2019-03-28
CA2688478C (en) 2015-10-27
US20190192423A1 (en) 2019-06-27
MY150450A (en) 2014-01-30
IL202501A (en) 2015-11-30
EA200971132A1 (en) 2010-04-30
CA2688478A1 (en) 2008-12-11
HK1141737A1 (en) 2010-11-19
CN101677959B (en) 2014-02-26
PT2500014T (en) 2018-11-21
DK2500014T3 (en) 2018-12-03
PT2164467T (en) 2017-01-13
ES2694401T3 (en) 2018-12-20
CN101677959A (en) 2010-03-24
RS58248B1 (en) 2019-03-29
TN2009000476A1 (en) 2011-03-31
CY1120891T1 (en) 2019-12-11
MX2009012856A (en) 2009-12-15
LT2500014T (en) 2019-01-25
EP3431077A1 (en) 2019-01-23
KR101631475B1 (en) 2016-06-20
EP2164467B1 (en) 2016-12-14
US20110052717A1 (en) 2011-03-03
ES2611020T3 (en) 2017-05-04
ME00959B (en) 2012-06-20
EA019284B1 (en) 2014-02-28
BRPI0812250B1 (en) 2020-03-03
SI2164467T1 (en) 2017-05-31
HRP20181854T1 (en) 2019-02-08
NZ582423A (en) 2011-10-28
MA31422B1 (en) 2010-06-01
BRPI0812250B8 (en) 2021-05-25
DK2164467T3 (en) 2017-01-30
KR20100023950A (en) 2010-03-04
EP2164467A2 (en) 2010-03-24
AP2009005088A0 (en) 2009-12-31
EP2500014B1 (en) 2018-08-08
PL2164467T3 (en) 2017-07-31
SI2500014T1 (en) 2019-02-28
CY1118434T1 (en) 2017-06-28
CO6251234A2 (en) 2011-02-21
BRPI0812250A2 (en) 2014-12-23
LT2164467T (en) 2017-01-25
JP5419169B2 (en) 2014-02-19
WO2008149320A2 (en) 2008-12-11
WO2008149320A3 (en) 2009-02-05
IL202501A0 (en) 2010-06-30
JP2010529106A (en) 2010-08-26
ZA200907940B (en) 2010-08-25
US10166181B2 (en) 2019-01-01

Similar Documents

Publication Publication Date Title
US20230082575A1 (en) Slow release pharmaceutical composition made of microparticles
EP0302582B1 (en) Drug delivery system and method of making the same
EP0744940B1 (en) Drugs, vaccines and hormones in polylactide coated microspheres
US4855134A (en) Sustained-release preparation
Kostanski et al. A novel in vitro release technique for peptide-containing biodegradable microspheres
KR20210007924A (en) Long-lasting composition comprising rivastigmine and method for preparing the same
WO2000040259A1 (en) Prolonged release microsphere encapsulating luteinizing hormone-releasing hormone analogues and method for preparing the same
JP2008506717A (en) Gonadotropin releasing hormone antagonist
JP2000509403A (en) Pharmaceutical compositions for sustained release of insoluble active ingredients
US20040126431A1 (en) Method for preparing microspheres containing a water-soluble substance
CN104107165A (en) Microsphere preparation of exenatide, preparation method and application thereof
CN101884622B (en) Benserazide sustained-release microspherical composition and preparation method thereof
ES2337419T3 (en) SUBCUTANEOUS IMPLANTS THAT RELEASE AN ACTIVE PRINCIPLE DURING A PROLONGED TIME PERIOD.
WO2024110835A1 (en) Use of nano-carriers for delivery of active agents

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER